Adalimumab: Difference between revisions
From IDWiki
(Created page with "* Human IgG1 monoclonal antibody against TNF-α * Indications include JIA, RA, Crohn disease, ankylosing spondylitis, chronic plaque psoriasis, and psori...") |
mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
* Human IgG1 monoclonal antibody against TNF-α |
* Human IgG1 monoclonal antibody against [[Tumour necrosis factor-α inhibitors|TNF-α]] |
||
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
||
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
||
[[Category:TNF-α inhibitors]] |
|||
[[Category: |
[[Category:Monoclonal antibodies]] |
||
Latest revision as of 00:43, 17 March 2022
- Human IgG1 monoclonal antibody against TNF-α
- Indications include JIA, RA, Crohn disease, ankylosing spondylitis, chronic plaque psoriasis, and psoriatic arthritis
- Infectious complications include bacterial infections (including severe pneumonia), TB, candidiasis, CMV, toxoplasmosis, and nocardiosis
